Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current.
暂无分享,去创建一个
G Rousseau | B. Drolet | G. Rousseau | P. Daleau | R. Cardinal | J. Turgeon | G. O'hara | J. Rail | P Geelen | R Cardinal | B Drolet | J Turgeon | J Rail | P. Geelen | P Daleau | J Bérubé | G E O'Hara | J. Bérubé | Jimmy Rail | Jacques Turgeon | Jocelyn Bérubé | Peter Geelen | Benoit Drolet | Guy Rousseau | René Cardinal | Gilles O'Hara
[1] J. Corbin,et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. , 1999, The American journal of cardiology.
[2] B. Drolet,et al. Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. , 1998, Circulation.
[3] S. Kaul,et al. Writing Group Members , 2022 .
[4] Jay S. Cohen. Should Patients be Given an Initial Low Test Dose of Sildenafil? , 2000, Drug safety.
[5] C. January,et al. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. , 1998, Biophysical journal.
[6] R. Clark,et al. Cisapride-induced dysrhythmia in a pediatric patient receiving extracorporeal life support. , 1996, Critical care medicine.
[7] I. Osterloh,et al. Overall cardiovascular profile of sildenafil citrate. , 1999, The American journal of cardiology.
[8] G. Muirhead,et al. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. , 2000, British journal of clinical pharmacology.
[9] P. Daleau,et al. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes. , 1995, Circulation.
[10] S. Priori. Exploring the Hidden Danger of Noncardiac Drugs , 1998, Journal of cardiovascular electrophysiology.
[11] F. Montorsi. Clinical safety of oral sildenafil citrate (VIAGRATM) in the treatment of erectile dysfunction—by Morales et al , 1998, International Journal of Impotence Research.
[12] P. Wright,et al. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.
[13] M. Goldenberg,et al. Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. , 1998, Clinical therapeutics.
[14] G. Kerchner,et al. Endogenous voltage‐gated potassium channels in human embryonic kidney (HEK293) cells , 1998, Journal of neuroscience research.
[15] Tom F. Lue,et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, New England Journal of Medicine.
[16] P. Daleau,et al. Modulation of HERG potassium channel properties by external pH , 1999, Pflügers Archiv.
[17] J. Spence,et al. Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition , 2000, Clinical pharmacokinetics.
[18] Conti Cr. VIAGRA, THE LATEST CARDIO-VASCULAR DRUG , 1998 .
[19] M. Nassar. Viagra®, the latest cardio‐vascular drug , 1999, Clinical cardiology.
[20] I. Goldstein,et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. , 1998, The New England journal of medicine.
[21] J. Lynch,et al. Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. , 1995, Circulation research.
[22] R. A. Murphy,et al. Sildenafil, a type-5 CGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. , 1998, The Journal of urology.